Positive Phase II For Sanofi-Chasing Valneva/GSK C.Diff Vaccine
This article was originally published in Scrip
Executive Summary
Valneva has reported positive topline Phase II data for its prophylactic vaccine candidate against Clostridium difficile infection. The product – which is partnered with GlaxoSmithKline – is the second in development behind Sanofi's prophylactic vaccine candidate, claims Valneva CEO Thomas Lingelbach. He also believes Valneva's product could offer advantages over Sanofi's product. Pfizer also has a prophylactic C. difficile vaccine candidate in Phase II development.